The MFDS IND approval status is an indicator of how actively domestic and overseas pharmaceutical and biotech companies use Korea as a clinical‑trial hub. In May 2025 the Korean Ministry of Food and Drug Safety (MFDS) approved 45 investigational new drug (IND) clinical trial applications. Of these, 31 approvals (≈69 %) were for compounds developed overseas, while 14 approvals (≈31 %) involved domestic projects. The high proportion of overseas projects reflects a regulation requiring foreign sponsors to collaborate with local contract research organizations (CROs) when running trials in Korea. This collaboration allows companies to leverage Korean infrastructure and patient diversity, underlining the country’s emergence as a global clinical‑trial hub.
Number of approvals and phase distribution
Among the 45 approvals, Phase 3 trials accounted for 18 cases (≈40 %), followed by 8 Phase 2 trials (17.8 %), 7 Phase 1/2 trials (15.6 %), 6 Phase 1 trials (13.3 %) and smaller numbers of Phase 1b, Phase 3b, Phase 4 and Phase 2/3 studies. The large share of late‑stage studies suggests that many drug candidates have passed initial safety evaluations and are now confirming efficacy, often through extension studies of multinational trials. At the same time, early‑stage trials (Phase 1 and Phase 1/2) represented nearly 29 %, indicating active exploratory research by domestic biotech companies.
Domestic versus overseas development
The 31 overseas approvals mainly involved extension studies sponsored by multinational pharmaceutical companies. Foreign sponsors must designate a local CRO partner and submit their trial outcomes to Korea’s Clinical Research Information Service (CRIS). Fourteen domestic approvals were mainly driven by biotech start‑ups and small pharmaceutical firms conducting Phase 1 or Phase 1/2 studies. These projects covered oncology, rare diseases and metabolic disorders, highlighting the diversity of Korea’s early‑stage pipeline.
Leading sponsors and therapeutic trends
In May the top sponsors were Medpace Inc., IQVIA Korea and PPD Development Pte Ltd, each with three approvals. SIMIC Korea and Novotech Asia Korea followed with two approvals each. Therapeutic analysis showed oncology dominating with 11 approvals, covering lung cancer, T‑cell lymphomas and other solid tumours. Neuromuscular and neurologic disorders accounted for five approvals, cardiovascular diseases four, metabolic disorders such as diabetes and obesity five, and immune‑related conditions including thrombocytopenia several cases. This diversity mirrors global research trends and suggests that Korea is not limited to a single therapeutic area.
Korean clinical‑trial environment and regulations
Korea offers a world‑class clinical‑trial environment with advanced medical facilities and trained personnel. The MFDS reviews clinical trial protocols and ensures safety and ethics, while Institutional Review Board (IRB) approval is also required. The Korean Good Clinical Practice (KGCP) guidelines align with the International Council for Harmonisation (ICH); the Personal Information Protection Act (PIPA) and MFDS guidelines strictly regulate data privacy and security. Sponsors must quickly report adverse events and continuously monitor safety, and foreign sponsors are required to partner with domestic CROs and disclose trial results through CRIS. These policies provide trust and efficiency for both domestic and international companies conducting trials in Korea.
Conclusion and outlook
The May 2025 MFDS IND approval statistics demonstrate that Korea remains an attractive trial site for domestic and international pharmaceutical and biotech companies. The 45 approvals represent continued growth compared with the same period last year, with a notable emphasis on late‑stage trials that signal rapid progress toward commercialization. While overseas compounds dominate, domestic biotech participation continues to expand, strengthening Korea’s research capacity. Rigorous reviews by the MFDS and IRBs, compliance with KGCP and robust data‑protection frameworks ensure credibility. These factors position Korea to grow beyond Asia as a global clinical‑trial hub.
Launching a clinical trial in Korea requires meticulous planning—from protocol drafting and regulatory strategy to CRO collaboration. Our company provides tailored quotation services for clinical‑trial planning and a newsletter that delivers the latest IND approval trends. Please contact us via the links below.
